Survival Gains

The CE‑mark and FDA approval were supported by data from the phase III PANOVA‑3 study, which demonstrated a statistically significant improvement in median overall survival (mOS) and significantly extended time to pain progression. The study's results are promising for advanced‑stage pancreatic cancer patients, potentially driving strong adoption as a treatment option.